{"nctId":"NCT04460326","briefTitle":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2020-12-07","type":"ACTUAL"},"conditions":["Type 2 Diabetes Treated With Insulin"],"count":137,"armGroups":[{"label":"Group 1 insulin glargine and Novolog","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin glargine","Drug: NovoLog","Other: Standard carbohydrate diet"]},{"label":"Group 2 insulin glargine and Fiasp","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin glargine","Drug: Insulin Fiasp","Other: Standard carbohydrate diet"]}],"interventions":[{"name":"Insulin glargine","otherNames":["Lantus®"]},{"name":"NovoLog","otherNames":["NovoLog®"]},{"name":"Insulin Fiasp","otherNames":["Fiasp®"]},{"name":"Standard carbohydrate diet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n1. English-speaking\n2. Males and female adult subjects admitted to Boston Medical Center to a medical or surgical floor.\n3. Consultation by the Inpatient Diabetes Service at Boston Medical Center is required prior to consent.\n4. Age ≥ 21 and \\<= 80 years.\n5. Diagnosed with type 2 diabetes at least 180 days prior to screening.\n6. Hyperglycemia during admission, as defined by a point of care and/or venous blood glucose ≥ 140 mg/dL.\n7. Prior to admission subjects must be using one of the following for outpatient diabetes management:\n\n   1. Insulin\n   2. ≥ 2 oral/injectable agents\n   3. One oral/injectable agent with a hemoglobin A1c of ≥ 8% within 3 months of enrollment.\n8. Patients who are expected to remain hospitalized for a minimum of 48 hours following CGM sensor placement.\n9. BMI \\<45 kg/m\\^2.\n10. Subjects must have insulin glargine dosing planned at bedtime for the duration of the study period. Morning and afternoon dosing of insulin glargine are exclusionary.\n\nExclusion criteria:\n\n1. Patients with a history of type 1 diabetes or late-onset autoimmune diabetes (LADA).\n2. Treatment or plan for treatment with glucocorticoids during the index hospitalization.\n3. Female patients who are pregnant (tested during hospitalization or screening) or breast-feeding during the hospitalization.\n4. Patients admitted with the following conditions: diabetic ketoacidosis, hyperosmolar hyperglycemic state, solid organ transplantation, or coronary artery bypass surgery.\n5. Prior diagnosis of gastroparesis or cirrhosis.\n6. Acute or chronic kidney disease with a serum creatinine of ≥ 2 mg/dL at the time of screening.\n7. Clinically significant nausea and/or vomiting or unable to consume more than 30 grams of carbohydrate at each meal.\n8. Patients expected to receive nothing by mouth (NPO) for \\>24 hours.\n9. Use of continuous or intermittent enteral feeding or parenteral nutrition.\n10. Patient receiving aspirin and/or vitamin C during the hospitalization.\n11. Any mental condition rendering the subject unable to provide informed consent.\n12. Patients currently incarcerated.\n13. Patients using \\>1 unit/kg/day of insulin prior to admission.\n14. Insulin pump usage within the 2 weeks prior to or during admission.\n15. Patients currently using real-time continuous glucose monitoring (CGM) or personal flash glucose monitoring system (FGM).\n16. Patients with a history of an allergy to any of the types of insulin or one of the excipients in the insulin used in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Postprandial Glucose Control","description":"Percent of time spent in the glycemic target range of 100-180 mg/dL in the 4 hour postprandial period will be assessed using a continuous glucose monitoring (CGM) system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.18","spread":"29.78"},{"groupId":"OG001","value":"45.22","spread":"32.63"}]}]}]},{"type":"SECONDARY","title":"Glycemic Control While Hospitalized","description":"Percent of time spent in the glycemic target range of 100-180 mg/dL during the duration of the study will be assessed using a continuous glucose monitoring (CGM) system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":"26.0"},{"groupId":"OG001","value":"39.9","spread":"26.6"}]}]}]},{"type":"SECONDARY","title":"Percent of Time Spent in Glycemic Range of 70-140 mg/dL","description":"Percent of time spent in the glycemic target range of 70-140 mg/dL during the duration of the study assessed using a continuous glucose monitoring (CGM) system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"18.4"},{"groupId":"OG001","value":"20.2","spread":"21.3"}]}]}]},{"type":"SECONDARY","title":"Percent of Time Spent With Hypoglycemia During Hospitalization","description":"The percent of time in three categories of hypoglycemia : \\<70 mg/dL, \\<54 mg/dL, and \\<40 mg/dL will be assessed using a CGM during hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"2.1"},{"groupId":"OG001","value":"1.52","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.6"},{"groupId":"OG001","value":"0.53","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.08"},{"groupId":"OG001","value":"0.10","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Percent of Nocturnal Time in Glycemic Target Range 100-180 mg/dL","description":"The percent of nocturnal time (from 00.01 AM to 5:59 AM) in the glycemic target range of 100-180 mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":"37.4"},{"groupId":"OG001","value":"42.1","spread":"40.7"}]}]}]},{"type":"SECONDARY","title":"Percent of Nocturnal Time Spent With Hypoglycemia","description":"The percent of nocturnal time (from 00.01 AM to 5:59 AM) in three categories of hypoglycemia: \\<70 mg/dL, \\<54 mg/dL, and \\<40 mg/dL will be assessed using CGM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"2.44"},{"groupId":"OG001","value":"1.12","spread":"4.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":"0.24"},{"groupId":"OG001","value":"0.22","spread":"1.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0.073","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Percent of Postprandial Time Spent With Level 1 Hyperglycemia","description":"The percent of time spent in level 1 hyperglycemia (181-239 mg/dL) will be assessed using CGM in the 4 hour postprandial period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"16.9"},{"groupId":"OG001","value":"23.3","spread":"19.2"}]}]}]},{"type":"SECONDARY","title":"Percent of Postprandial Time Spent With Level 2 Hyperglycemia","description":"The percent of time spent in level 2 hyperglycemia (\\>240 mg/dL) will be assessed using CGM in the 4 hour postprandial period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"31.2"},{"groupId":"OG001","value":"26.7","spread":"31.2"}]}]}]},{"type":"SECONDARY","title":"Percent of Postprandial Time Spent With Hypoglycemia","description":"The percent of postprandial time in three categories of hypoglycemia will be assessed: \\<70 mg/dL, \\<54 mg/dL, and \\<40 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"2.32"},{"groupId":"OG001","value":"0.76","spread":"3.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.85"},{"groupId":"OG001","value":"012","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.07"},{"groupId":"OG001","value":"0.03","spread":"0.19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["bleeding at CGM site"]}}}